UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diabetes and Stroke: What Are the Connections?

Journal of stroke, 2023-01, Vol.25 (1), p.26-38

2023

Volltextzugriff (PDF)

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

Clinical therapeutics, 2016-12, Vol.38 (12), p.2654-2664.e1

2016

Volltextzugriff (PDF)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Diabetes, obesity & metabolism, 2022-09, Vol.24 (9), p.1861-1868

2022

Volltextzugriff (PDF)

120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2

Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1

2024

Volltextzugriff (PDF)

770-P: Efficacy and Safety of Tirzepatide in Participants Who Achieved Fasting Serum Glucose Targets at 52 Weeks in SURPASS-3 and SURPASS-4

Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1

2024

Volltextzugriff (PDF)

826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function-ONWARDS 1–5

Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1

2024

Volltextzugriff (PDF)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

Diabetes, obesity & metabolism, 2023-01, Vol.25 (1), p.68-77

2023

Volltextzugriff (PDF)

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Current opinion in cardiology, 2006-07, Vol.21 (4), p.400-404

2006

Volltextzugriff (PDF)

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation

Diabetes (New York, N.Y.), 2024-06, Vol.73, p.1

2024

Volltextzugriff (PDF)

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.965-974

2023

Volltextzugriff (PDF)

Patients achieving a HbA1c <5.7% with ≥5% weight loss and without hypoglycemia: A post hoc analysis of SURPASS 1 to 5

The American heart journal, 2024-01, Vol.267, p.132-133

2024

Volltextzugriff (PDF)

Patients achieving a HbA1c

The American heart journal, 2024-01, Vol.267, p.132

2024

Volltextzugriff (PDF)

Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

The lancet. Diabetes & endocrinology, 2020-05, Vol.8 (5), p.357-360

2020

Volltextzugriff (PDF)

Efficacy of tirzepatide 5, 10 and 15mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Diabetes, obesity & metabolism, 2022-09, Vol.24 (9), p.1861-1868

2022

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults With Type 2 Diabetes in Canada: A Cross-sectional Study

Canadian journal of diabetes, 2023-07, Vol.47 (5), p.398-404

2023

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Adults With Type 2 Diabetes Care and Clinical Parameters in a Primary Care Setting in Ontario, Canada: A Cross-sectional Study

Canadian journal of diabetes, 2023-06, Vol.47 (4), p.345-351

2023

Volltextzugriff (PDF)

Management of Type 2 Diabetes in People With Renal Impairment

The Journal of Family Practice, 2021-05, Vol.70 (4 Suppl)

2021

Volltextzugriff (PDF)

206 - Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

Obesity research & clinical practice, 2024-09, Vol.18 (5), p.34-35

2024

Volltextzugriff (PDF)

Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

Obesity research & clinical practice, 2024-09, Vol.18 (5), p.S34-S35

2024

Volltextzugriff (PDF)

Cardiovascular Risk Reduction in Patients with Type 2 Diabetes

Journal of clinical outcomes management, 2017-02, Vol.24 (2), p.1

2017

Volltextzugriff (PDF)

Update on the Canadian Diabetes Association 2008 clinical practice guidelines

Canadian family physician, 2009-01, Vol.55 (1), p.39-43

2009

Volltextzugriff (PDF)

PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease

Diabetes, obesity & metabolism, 2008-09, Vol.10 (9), p.691-698

2008

Volltextzugriff (PDF)

Thiazolidinedione-induced congestive heart failure

The Annals of pharmacotherapy, 2004-05, Vol.38 (5), p.817-820

2004

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Diabetes
(13)
Diabetes Mellitus
(13)
Humans
(11)
Endocrinology & Metabolism
(10)
Hypoglycemia
(6)
Insulin
(6)
Diabetes Mellitus, Type 2 - Drug Therapy
(5)
Hypoglycemic Agents - Therapeutic Use
(4)
Adult
(3)
Antidiabetics
(3)
Body Weight
(3)
Canada
(3)
Cardiovascular Disease
(3)
Cardiovascular System & Cardiology
(3)
Clinical Trials
(3)
Hypoglycemic Agents - Adverse Effects
(3)
Male
(3)
Patients
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Diabetes and Stroke: What Are the Connections?

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2

770-P: Efficacy and Safety of Tirzepatide in Participants Who Achieved Fasting Serum Glucose Targets at 52 Weeks in SURPASS-3 and SURPASS-4

826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function-ONWARDS 1–5

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies

Patients achieving a HbA1c <5.7% with ≥5% weight loss and without hypoglycemia: A post hoc analysis of SURPASS 1 to 5

Patients achieving a HbA1c

Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

Efficacy of tirzepatide 5, 10 and 15mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults With Type 2 Diabetes in Canada: A Cross-sectional Study

Impact of the COVID-19 Pandemic on Adults With Type 2 Diabetes Care and Clinical Parameters in a Primary Care Setting in Ontario, Canada: A Cross-sectional Study

Reflecting on a Year at the Helm of Diabetes Care

Management of Type 2 Diabetes in People With Renal Impairment

"The Times They Are A-Changin'" at Diabetes Care

206 - Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

Cardiovascular Risk Reduction in Patients with Type 2 Diabetes

Update on the Canadian Diabetes Association 2008 clinical practice guidelines

PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease

Thiazolidinedione-induced congestive heart failure

Suchergebnisse filtern